Key result
ApHCM is linked to a more favorable disease course than non-apical HCM, driven by less fibrosis.
Why the study?
Does apical hypertrophic cardiomyopathy have a more benign clinical course and different imaging characteristics compared to non-apical hypertrophic cardiomyopathy?
Does apical hypertrophic cardiomyopathy have a more benign clinical course and different imaging characteristics compared to non-apical hypertrophic cardiomyopathy?
Apical hypertrophic cardiomyopathy is associated with less myocardial fibrosis, milder diastolic dysfunction, and a more benign clinical course compared to non-apical variants.
No takes yet. Share an insight, caveat, or question.
ApHCM may confer milder disease; supports subtype differences but leaves open prospective validation for risk stratification.
Kim et al. (2015) studied this question. Apical hypertrophic cardiomyopathy (ApHCM) had less myocardial fibrosis and milder diastolic dysfunction, leading to a more favorable disease course than non-apical HCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: